Target Name: ZNF101
NCBI ID: G94039
Review Report on ZNF101 Target / Biomarker Content of Review Report on ZNF101 Target / Biomarker
ZNF101
Other Name(s): Zinc finger protein 12 | Zinc finger protein 101 | Zinc finger protein 101 (isoform 1) | zinc finger protein 101 | zinc finger protein 12 | zinc finger protein HZF12 | zinc finger protein 101 (Y2) | Zinc finger protein 101 (Y2) | Zinc finger protein 101, transcript variant 1 | ZN101_HUMAN | ZNF101 variant 1 | HZF12 | Zinc finger protein HZF12

ZNF101: A Potential Drug Target for Cancer

ZNF101 (Zinc Finger Protein 12) is a protein that is expressed in almost all eukaryotic cells and plays an important role in many biological processes. ZNF101 can be regulated through gene knockout, overexpression or mutation to control biological processes such as cell cycle, proliferation, differentiation and apoptosis.

ZNF101 is a zinc-finger transcription factor whose unique structural domain includes a zinc finger, a short 伪-helix and a long 尾-coil. The zinc finger is the most striking feature of ZNF101 and is also a key part of its interaction with other proteins. Zinc fingers can bind to DNA and regulate gene expression and DNA replication.

In cancer, ZNF101 expression levels often change. Studies have shown that the expression level of ZNF101 is closely related to the prognosis and treatment response of many cancers, such as lung cancer, liver cancer, breast cancer, etc. In addition, the expression level of ZNF101 is also closely related to the pathogenesis of various cancers, such as abnormal regulation of biological processes such as cell cycle, proliferation, differentiation, and apoptosis.

Because ZNF101 plays an important role in many biological processes, it is considered a potential drug target or biomarker. Currently, there are many studies devoted to developing ZNF101 as a drug target or biomarker to treat various cancers.

In drug research, ZNF101 is often used as a target or biomarker for treating cancer, mainly by interfering with its function. Several studies have demonstrated ZNF101's effectiveness in treating a variety of cancers. For example, studies have shown that overexpression of ZNF101 can lead to the progression and invasion of cancers such as lung cancer, liver cancer, and breast cancer, and inhibiting the expression of ZNF101 can significantly inhibit the progression and invasion of these cancers. In addition, some studies have also shown that the expression level of ZNF101 is closely related to the survival rate and treatment response of various cancers.

In addition to its potential role in treating cancer, ZNF101 is used as an indicator in many other biological studies. For example, studies have shown that the expression level of ZNF101 can be used to predict the survival rate of cancer patients and regulate the function of immune cells in the tumor microenvironment. In addition, ZNF101 also interacts with a variety of proteins, such as p21, p53 and p63, etc. These interactions may have an important impact on the function of ZNF101.

ZNF101 is a protein expressed in all eukaryotic cells and plays an important role in many biological processes. ZNF101 can be regulated through gene knockout, overexpression or mutation to control biological processes such as cell cycle, proliferation, differentiation and apoptosis. In cancer, the expression level of ZNF101 often changes and is therefore considered a potential drug target or biomarker. Currently, there are many studies devoted to developing ZNF101 as a drug target or biomarker to treat various cancers.

Protein Name: Zinc Finger Protein 101

Functions: May be involved in transcriptional regulation

The "ZNF101 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF101 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ZNF106 | ZNF107 | ZNF112 | ZNF114 | ZNF117 | ZNF12 | ZNF121 | ZNF124 | ZNF131 | ZNF132 | ZNF133 | ZNF134 | ZNF135 | ZNF136 | ZNF137P | ZNF138 | ZNF14 | ZNF140 | ZNF141 | ZNF142 | ZNF143 | ZNF146 | ZNF148 | ZNF154 | ZNF155 | ZNF157 | ZNF16 | ZNF160 | ZNF165 | ZNF169 | ZNF17 | ZNF174 | ZNF175 | ZNF177 | ZNF18 | ZNF180 | ZNF181 | ZNF182 | ZNF184 | ZNF185 | ZNF189 | ZNF19 | ZNF195 | ZNF197 | ZNF2 | ZNF20 | ZNF200 | ZNF202 | ZNF204P | ZNF205 | ZNF205-AS1 | ZNF207 | ZNF208 | ZNF209P | ZNF211 | ZNF212 | ZNF213 | ZNF213-AS1 | ZNF214 | ZNF215 | ZNF217 | ZNF219 | ZNF22 | ZNF22-AS1 | ZNF221 | ZNF222 | ZNF223 | ZNF224 | ZNF225 | ZNF225-AS1 | ZNF226 | ZNF227 | ZNF229 | ZNF23 | ZNF230 | ZNF232 | ZNF232-AS1 | ZNF233 | ZNF234 | ZNF235 | ZNF236 | ZNF236-DT | ZNF239 | ZNF24 | ZNF248 | ZNF25 | ZNF250 | ZNF251 | ZNF252P | ZNF252P-AS1 | ZNF253 | ZNF254 | ZNF256 | ZNF257 | ZNF26 | ZNF260 | ZNF263 | ZNF264 | ZNF266 | ZNF267